Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines. This expansion of their 2016 collaboration will ...

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines.

"The bumpy ride gets bumpier," she said. Moderna's partnership with Merck on a cancer vaccine shows potential, but it is years away from generating meaningful revenue. Moderna will outline its ...

In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157), in combination with Keytruda, for treating adjuvant melanoma and non-small ...

In addition to treating respiratory viruses, Moderna has a partnership with Merck & Co. MRK to develop cancer vaccines. This is a way for Moderna to take a seat at the table of personalized medicine.

The partnership will cover research and development projects, programs and activities focused on malaria and schistosomiasis, as well as related infections. “Merck is pleased to engage with ...

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines. This expansion of their 2016 collaboration will ...